Liberal US Mayors Join European Pact to Counter National Governments

The Department of Health and Human Services continues to withhold details on the duties assigned to David Geier, a researcher long associated with studies examining possible vaccine side effects. Secretary Robert F. Kennedy Jr. pledged in April to supply Geier's contract to the Senate Finance Committee within days, yet weeks later the document has not arrived. A spokesman for Senator Ben Ray Luján noted that repeated inquiries have produced no response.

Geier and his late father once operated clinics and research groups that investigated links between vaccine preservatives and developmental disorders. Their work drew sharp rebukes from mainstream medical organizations, which cited methodological shortcomings and urged caution against unproven interventions. One treatment they explored involved a hormone suppressant, drawing accusations that the approach risked harm to children. Critics have labeled the pair's efforts as outside accepted practice.

Public agencies have faced similar transparency shortfalls before. Past episodes, from shifting guidance on blood supplies during disease outbreaks to revisions on dietary recommendations, illustrate how official positions can change once new data surface. Supporters of broader inquiry argue that dismissing every challenge to vaccine schedules as fringe overlooks documented cases where adverse events were later acknowledged. The Vaccine Injury Compensation Program itself exists because some injuries occur, even if their frequency remains contested in statistical debates.

Opponents of Geier's involvement contend that his presence signals a tilt away from settled science. They point to the American Academy of Pediatrics critique of earlier papers linking thimerosal to autism rates. Those papers were faulted for incomplete controls and overstated conclusions. Yet the academy's own statements have not prevented ongoing litigation and parental concerns over cumulative vaccine schedules.

Government hiring practices add another layer. Agencies routinely engage outside experts on narrow topics without immediate public disclosure of every assignment. The current refusal to clarify Geier's scope may reflect standard personnel procedures rather than evasion. Still, the delay tests assurances that the department intends full cooperation with oversight committees.

Data on autism prevalence have risen steadily over decades while vaccine formulations changed. Researchers continue to examine genetic factors, environmental exposures, and diagnostic expansion as possible contributors. Geier's prior focus on one narrow hypothesis does not automatically disqualify examination of safety signals, provided methods meet rigorous standards. Historical examples abound of initially fringe questions that later prompted protocol adjustments, from recognition of certain drug interactions to revised screening intervals.

Kennedy's leadership has already prompted discussion about balancing disease prevention with individualized risk assessment. Federal health policy has long weighed population benefits against individual outcomes, a tension visible in debates over school mandates and exemption rules. Clear delineation of roles for any consultant would help separate legitimate data review from policy shifts.

Until the contract details appear, observers must rely on public records of past studies rather than current assignments. The episode underscores recurring friction between executive branch staffing choices and legislative demands for information. Both sides claim protection of public health; resolution hinges on documented evidence rather than institutional reputation alone.